“Establishing a Risk Model for Diabetic Nephropathy and Addressing the Therapeutic Effect of  Combined Epalrestat- Dapagliflozin Regimen” (2024) Iranian Journal of Kidney Diseases, 18(05). doi:10.52547/ax1vqh41.